A brief overview of clinical significance of novel Notch2 regulators

References

• D’Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. Curr Top Dev Biol. 2010;92:1–5.
   PubMed Web of Science ®Google Scholar
• Bray S, Bernard F. Notch targets and their regulation. Curr Top Dev Biol. 2010;92:253–275.
   PubMed Web of Science ®Google Scholar
• Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–233. doi:10.1016/j.cell.2009.03.045.
   PubMed Web of Science ®Google Scholar
• Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell. 2009;16:633–647. doi:10.1016/j.devcel.2009.03.010.
   PubMed Web of Science ®Google Scholar
• Kovall RA, Blacklow SC. Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Curr Top Dev Biol. 2010;92:31–71.
   PubMed Web of Science ®Google Scholar
• Varadkar P, Kraman M, Despres D, Ma G, Lozier J, McCright B Notch2 is required for the proliferation of cardiac neural crest-derived smooth muscle.
   Google Scholar
• Xiu MX, Liu YM. The role of oncogenic Notch2 signaling in cancer: a novel therapeutic target. Am J Cancer Res. 2019 May 1;9(5):837–854. 2019. uscle cells. Dev Dyn. 2008;237(4):1144‐1152. doi:10.1002/dvdy.21502.
   PubMed Web of Science ®Google Scholar
• Pancewicz-Wojtkiewicz J, Eljaszewicz A, Kowalczuk O, Niklinska W, Charkiewicz R, Kozłowski M, Miasko A, Moniuszko M. Prognostic significance of Notch ligands in patients with non-small cell lung cancer. Oncol Lett. 2017 Jan;13(1):506–510. doi:10.3892/ol.2016.5420.
   PubMed Web of Science ®Google Scholar
• Brzozowa-Zasada M, Piecuch A, Michalski M, Segiet O, Kurek J, Harabin-Słowińska M, Wojnicz R. Notch and its oncogenic activity in human malignancies. Eur Surg. 2017;49(5):199–209. doi:10.1007/s10353-017-0491-z.
   PubMedGoogle Scholar
• Joanna P, Leszek BP. Differential Notch1 and Notch2 expression in non-small cell lung cancer. Progress Health Sci. 2019;1(9):8–12.
   Google Scholar
• Huang TT, Ping YH, Wang AM, Ke CC, Fang WL, Huang KH, Lee HC, Chi CW, Yeh TS. The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis. Oncotarget. 2015;6:18012. doi:10.18632/oncotarget.4000.
   PubMedGoogle Scholar
• Chen XB, Li W, Chu AX. MicroRNA-133a inhibits gastric cancer cells growth, migration, and epithelial-mesenchymal transition process by targeting presenilin 1. J Cell Biochem. 2019;120:470–480. doi:10.1002/jcb.27403.
   PubMedGoogle Scholar
• Fiaschetti G, Schroeder C, Castelletti D, Arcaro A, Westermann F, Baumgartner M, Shalaby T, Grotzer MA. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. Acta Neuropathologica Commun. 2014;2:39. doi:10.1186/2051-5960-2-39.
   PubMed Web of Science ®Google Scholar
• Zou Y, Fang F, Ding YJ, Dai MY, Yi X, Chen C, Tao ZZ, Chen SM. Notch2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinoma. Mol Med Rep. 2016;14:3517–3524. doi:10.3892/mmr.2016.5688.
   PubMed Web of Science ®Google Scholar
• Kamga PT, Bassi G, Cassaro AC, Stradoni R, Midolo M, Perbellini O, Krampera M. Role of stromal cell-mediated Notch signaling in AML survival and resistance to chemotherapy. Oncotarget. 2016;7:21713–21727. doi:10.18632/oncotarget.7964.
   PubMedGoogle Scholar
• Scharf DH, Brakhage AA, Mukherjee PK. Gliotoxin–bane or boon? Environ Microbiol. 2016 Apr;18(4):1096–1109. doi:10.1111/1462-2920.13080.
   PubMed Web of Science ®Google Scholar
• Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, et al. Gliotoxin targets nuclear NOTCH2 in human solid tumor derived cell lines in vitro and inhibits melanoma growth in xenograft mouse model. Front Pharmacol. 2017 Jul 7;8:319. doi:10.3389/fphar.2017.00319.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Friedmann DR, VanderWielen BD, Collins KJ, Kovall RA. Characterization of CSL (CBF-1, Su(H), Lag-1) mutants reveals differences in signaling mediated by Notch1 and Notch2. J Biol Chem. 2012 Oct 12;287(42):34904–34916. doi:10.1074/jbc.M112.403287.
   PubMed Web of Science ®Google Scholar
• Hubmann R, Düchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Hölbl A, Vanura K, Le T, Look T, et al. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2010 Mar;148(6):868–878. doi:10.1111/j.1365-2141.2009.08024.x.
   PubMed Web of Science ®Google Scholar
• Hubmann R, Hilgarth M, Schnabl S, Ponath E, Reiter M, Demirtas D, Sieghart W, Valent P, Zielinski C, Jäger U, et al. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2013 Mar;160(5):618–629. doi:10.1111/bjh.12183.
   PubMed Web of Science ®Google Scholar
• Lu H, Jiang Z. Advances in antibody therapeutics targeting small-cell lung cancer. Adv Clin Exp Med. 2018 Sep;27(9):1317–1323. doi:10.17219/acem/70159.
   PubMed Web of Science ®Google Scholar
• Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015 May 1;21(9):2084–2095. doi:10.1158/1078-0432.CCR-14-2808.
   PubMed Web of Science ®Google Scholar
• Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012;30:2307–2313. doi:10.1200/JCO.2011.39.1540.
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res. 2015;21:60–67. doi:10.1158/1078-0432.CCR-14-0607.
   PubMed Web of Science ®Google Scholar
• Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005;435:964–968. doi:10.1038/nature03589.
   PubMed Web of Science ®Google Scholar
• van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959–963. doi:10.1038/nature03659.
   PubMed Web of Science ®Google Scholar
• Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, Xu L, Dupont J, Stagg RJ, Tolcher, et al. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. A Invest New Drugs. 2019 Aug;37(4):722–730. doi:10.1007/s10637-018-0714-6.
   PubMed Web of Science ®Google Scholar
• Ho RX, Meyer RD, Chandler KB, Ersoy E, Park M, Bondzie PA, Rahimi N, Xu H, Costello CE, Rahimi N. MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth. J Mol Cell Biol. 2018 Jun 1;10(3):195–204. doi:10.1093/jmcb/mjy002.
   PubMed Web of Science ®Google Scholar
• Deng J, Liu A-D, Hou G-Q, Zhang X, Ren K, Chen X-Z, Li SSC, Wu Y-S, Cao X. N-acetylcysteine decreases malignant characteristics of glioblastoma cells by inhibiting Notch2 signaling. J Exp Clin Cancer Res. 2019;38:2. doi:10.1186/s13046-018-1016-8.
   PubMed Web of Science ®Google Scholar
• Wu X, Chen B, Shi H, Zhou J, Zhou F, Cao J, Sun X. MiR-758-3p suppresses human bladder cancer cell proliferation, migration and invasion by targeting NOTCH2. Exp Ther Med. 2019 May;17(5):4273–4278. doi:10.3892/etm.2019.7400.
   PubMed Web of Science ®Google Scholar
• Hua CB, Song SB, Ma HL, Li XZ. MiR-1-5p is down-regulated in gallbladder carcinoma and suppresses cell proliferation, migration and invasion by targeting Notch2. Pathol Res Pract. 2019 Jan;215(1):200–208. doi:10.1016/j.prp.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Wang X, Meng Q, Qiao W, Ma R, Ju W, Hu J, Lu H, Cui J, Jin Z, Zhao Y, et al. miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Stem Cell Res Ther. 2018 Nov 23;9(1):327. doi:10.1186/s13287-018-1072-1.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, Liu Z, Xu Q, Liu S, Xiao D, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020 Mar 2;19(1):47. doi:10.1186/s12943-020-01171-z.
   PubMed Web of Science ®Google Scholar
• Li H, Wang Y. Long noncoding RNA (lncRNA) MIR22HG suppresses gastric cancer progression through attenuating NOTCH2 signaling. Med Sci Monit. 2019 Jan 23;25:656–665. doi:10.12659/MSM.912813.
   PubMed Web of Science ®Google Scholar